Payment overview · 2025
General Payments
$4,445.98
194 reported records · 30 companies
Healthcare provider profile · identity verified
Alejandro Octavio Roca, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH MIAMI, FL · NPI 1629034343
Verified facts
What the public records show
CMS Open Payments records show Alejandro Octavio Roca, M.D. received $4,445.98 in general payments during 2025 across 194 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Benlysta, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Nexletol, Nurtec Odt, Otezla, Ozempic, Prolia, Recorlev, Rexulti, Rinvoq, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tymlos by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
Xeris Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RECORLEV as an associated drug or biological on 10044 records involving 3629 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Recorlev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $805.74 | 18.1% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $451.50 | 10.2% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $412.85 | 9.3% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $331.12 | 7.5% | 11 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $255.79 | 5.8% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $215.89 | 4.9% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $195.09 | 4.4% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $184.66 | 4.2% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.27 | 3.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $146.73 | 3.3% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.85 | 3.2% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.53 | 3.2% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $132.60 | 3.0% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $116.79 | 2.6% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $95.89 | 2.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.62 | 2.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $90.25 | 2.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.72 | 1.8% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.47 | 1.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.81 | 1.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $63.24 | 1.4% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.31 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.74 | 0.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.35 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.07 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.57 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.01 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.03 | 0.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.42 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,445.98 | 194 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $600.80 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $311.78 | 14 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $255.79 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $231.87 | 6 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $218.97 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $204.24 | 11 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $195.09 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $184.66 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $164.24 | 12 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $143.96 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $142.43 | 6 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $132.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.27 | 7 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $124.25 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $120.60 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.85 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $109.23 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $106.43 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.62 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $90.25 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.59 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.72 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $72.64 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.81 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.58 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.58 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $33.31 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.39 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| SYNJARDY Normalized: synjardy |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.83 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 115 | exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 258 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 511 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 230 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 78 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 339 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 38 | exact normalized | Medicare Part D |
| RECORLEV recorlev |
2025 | Recorlev | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 112 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
154 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
511 | 120 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 54 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
54 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
339 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
112 | 38 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
115 | 114 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
258 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 33 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Xeris Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | RECORLEV open payments reported associated product |
CMS Open Payments — General Payments 10044 supporting records · 3629 recipient NPIs · example record 1250146588 |
Recorlev · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1680 | 462 |
| Levothyroxine Sodium | Levothyroxine Sodium | 943 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 896 | 267 |
| Amlodipine Besylate | Amlodipine Besylate | 669 | 185 |
| Gabapentin | Gabapentin | 656 | 165 |
| Alprazolam | Alprazolam | 618 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 574 | 158 |
| Pantoprazole Sodium | Pantoprazole Sodium | 537 | 163 |
| Omeprazole | Omeprazole | 535 | 139 |
| Farxiga | Dapagliflozin Propanediol | 511 | 120 |
| Metformin Hcl | Metformin Hcl | 424 | 130 |
| Glimepiride | Glimepiride | 383 | 102 |
| Prednisone | Prednisone | 374 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 372 | 114 |
| Meloxicam | Meloxicam | 371 | 87 |
| Mounjaro | Tirzepatide | 339 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 98 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 315 | 92 |
| Trazodone Hcl | Trazodone Hcl | 290 | 79 |
| Losartan Potassium | Losartan Potassium | 273 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 269 | 97 |
| Eliquis | Apixaban | 258 | 67 |
| Benazepril Hcl | Benazepril Hcl | 254 | 70 |
| Lisinopril | Lisinopril | 249 | 72 |
| Ezetimibe | Ezetimibe | 242 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 66 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 234 | 72 |
| Vascepa | Icosapent Ethyl | 234 | 51 |
| Jardiance | Empagliflozin | 230 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 60 |
| Bumetanide | Bumetanide | 228 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 65 |
| Donepezil Hcl | Donepezil Hcl | 221 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 218 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 211 | 44 |
| Allopurinol | Allopurinol | 203 | 50 |
| Famotidine | Famotidine | 200 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 31 |
| Temazepam | Temazepam | 179 | 27 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 174 | 37 |
| Telmisartan | Telmisartan | 174 | 45 |
| Potassium Chloride | Potassium Chloride | 172 | 38 |
| Tramadol Hcl | Tramadol Hcl | 169 | 33 |
| Clonazepam | Clonazepam | 168 | 38 |
| Folic Acid | Folic Acid | 165 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 162 | 65 |
| Ozempic | Semaglutide | 160 | 30 |
| Sertraline Hcl | Sertraline Hcl | 160 | 44 |
| Alendronate Sodium | Alendronate Sodium | 156 | 38 |
| Synthroid | Levothyroxine Sodium | 154 | 34 |
| Myrbetriq | Mirabegron | 153 | 31 |
| Ibuprofen | Ibuprofen | 150 | 40 |
| Atenolol | Atenolol | 146 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 37 |
| Pregabalin | Pregabalin | 144 | 31 |
| Spironolactone | Spironolactone | 137 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 35 |
| Methotrexate | Methotrexate Sodium | 134 | 33 |
| Leflunomide | Leflunomide | 132 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 128 | 57 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 125 | 100 |
| Azithromycin | Azithromycin | 121 | 109 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 120 | 27 |
| Fenofibrate | Fenofibrate | 118 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 118 | 29 |
| Risedronate Sodium | Risedronate Sodium | 117 | 37 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 115 | 114 |
| Lorazepam | Lorazepam | 115 | 14 |
| Naproxen | Naproxen | 114 | 27 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 113 | 42 |
| Rybelsus | Semaglutide | 112 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 90 |
| Mirtazapine | Mirtazapine | 110 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 110 | 29 |
| Memantine Hcl | Memantine Hcl | 106 | 28 |
| Carvedilol | Carvedilol | 102 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 99 | 37 |
| Glyxambi | Empagliflozin/Linagliptin | 97 | 22 |
| Simvastatin | Simvastatin | 97 | 28 |
| Finasteride | Finasteride | 94 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 93 | 40 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 92 | 28 |
| Buspirone Hcl | Buspirone Hcl | 92 | 37 |
| Ketoconazole | Ketoconazole | 90 | 42 |
| Furosemide | Furosemide | 88 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 25 |
| Montelukast Sodium | Montelukast Sodium | 86 | 27 |
| Celecoxib | Celecoxib | 85 | 26 |
| Linzess | Linaclotide | 81 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 19 |
| Rinvoq | Upadacitinib | 80 | 13 |
| Meclizine Hcl | Meclizine Hcl | 79 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 78 | 23 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 78 | 15 |
| Humalog Kwikpen U-200 | Insulin Lispro | 78 | 14 |
| Kerendia | Finerenone | 78 | 17 |
| Bupropion Xl | Bupropion Hcl | 77 | 26 |
| Irbesartan | Irbesartan | 77 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 70 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 18 |
| Metformin Hcl Er | Metformin Hcl | 69 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 68 | 17 |
| Xarelto | Rivaroxaban | 68 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 18 |
| Tradjenta | Linagliptin | 66 | 13 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 65 | 19 |
| Clonidine | Clonidine | 65 | 14 |
| Mupirocin | Mupirocin | 65 | 44 |
| Aripiprazole | Aripiprazole | 64 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Ammonium Lactate | Ammonium Lactate | 63 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 63 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 62 | 20 |
| Valacyclovir | Valacyclovir Hcl | 62 | 18 |
| Nystatin | Nystatin | 61 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 12 |
| Valsartan | Valsartan | 57 | 14 |
| Repatha Sureclick | Evolocumab | 56 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 39 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 47 |
| Midodrine Hcl | Midodrine Hcl | 52 | 14 |
| Chlorthalidone | Chlorthalidone | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 50 | 18 |
| Hydrocortisone | Hydrocortisone | 50 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 39 |
| Entresto | Sacubitril/Valsartan | 48 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 47 | suppressed |
| Benlysta | Belimumab | 47 | suppressed |
| Livalo | Pitavastatin Calcium | 47 | 15 |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 13 |
| Otezla | Apremilast | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 21 |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Lansoprazole | Lansoprazole | 44 | 18 |
| Nifedipine Er | Nifedipine | 44 | 12 |
| Repatha Syringe | Evolocumab | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Acyclovir | Acyclovir | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Doxepin Hcl | Doxepin Hcl | 42 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Ciclopirox | Ciclopirox | 40 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 20 |
| Humira(Cf) | Adalimumab | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 13 |
| Premarin | Estrogens, Conjugated | 39 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Prolia | Denosumab | 38 | 25 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | 15 |
| Amoxicillin | Amoxicillin | 37 | 32 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Ramipril | Ramipril | 35 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 33 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 33 | suppressed |
| Ssd | Silver Sulfadiazine | 33 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Nateglinide | Nateglinide | 31 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | 15 |
| Enbrel Sureclick | Etanercept | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 12 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 22 |
| Colchicine | Colchicine | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 24 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 23 |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Sulfasalazine | Sulfasalazine | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Humira(Cf) Pen | Adalimumab | 20 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Cabergoline | Cabergoline | 18 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Recorlev | Levoketoconazole | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,445.98 · 194 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACTHAR, AIRSUPRA, AREXVY, Auvelity, BENLYSTA, BREZTRI, Bimzelx, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, ENBREL, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, RECORLEV, REPATHA, REXULTI, RINVOQ, Rybelsus, SHINGRIX, SKYRIZI, SPRAVATO, SYNJARDY, TAVNEOS, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 31 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error